FDA questions antidepressant safety for children.
Oransky
Ivan
I
D000293:Adolescent; D026683:Advisory Committees; D000367:Age Factors; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D000075202:Contraindications; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D013405:Suicide / Q000523:psychology; D014481:United States; D014486:United States Food and Drug Administration; D000092864:Suicide Prevention
D000928:Antidepressive Agents; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors